Abstract
Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Graphical Abstract
Current Vascular Pharmacology
Title:Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Volume: 15 Issue: 4
Author(s): Kodappully Sivaraman Siveen, Kirti Prabhu, Roopesh Krishnankutty, Shilpa Kuttikrishnan, Magdalini Tsakou, Feras Q. Alali, Said Dermime, Ramzi M. Mohammad and Shahab Uddin*
Affiliation:
- Translational Research Institute, Academic Health System, Hamad Medical Corporation, PO Box 3050, Doha,Qatar
Keywords: VEGF, tumour angiogenesis, angiogenic balance, anti-VEGF therapy, extracellular matrix, food and drug administration.
Abstract: Angiogenesis is defined as the physiological process by which new blood vessels develop from pre-existing vessels; either by sprouting or intussusception. Inhibition of angiogenesis is one of the most encouraging strategies to manage the growth and metastasis of cancers. The functional and proliferative status of blood vessels is regulated by the balance between various key molecules that either stimulate or inhibit angiogenesis. During quiescence, the “angiogenic switch” is “off”. However, during tumour development pro-angiogenic factors such as vascular endothelial growth factor (VEGF), basic and acidic fibroblast growth factor, tumour necrosis factor-α and interleukin-1 are pathologically enhanced. Persistent growth of tumour directed capillary networks creates a favourable microenvironment, promoting cancer growth, progression and metastasis. VEGF, particularly VEGF-A, is a key angiogenic factor. Targeting VEGF, its receptors and the downstream signaling cascade, is a viable strategy to prevent tumour growth and metastasis. The present review discusses the role of VEGF in tumour angiogenesis and the current understanding of anti-VEGF therapies as well as refractoriness of anti-angiogenesis cancer therapy.
Export Options
About this article
Cite this article as:
Siveen Sivaraman Kodappully , Prabhu Kirti , Krishnankutty Roopesh , Kuttikrishnan Shilpa , Tsakou Magdalini , Alali Q. Feras , Dermime Said , Mohammad M. Ramzi and Uddin Shahab *, Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges, Current Vascular Pharmacology 2017; 15 (4) . https://dx.doi.org/10.2174/1570161115666170105124038
DOI https://dx.doi.org/10.2174/1570161115666170105124038 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Pathophysiology of Atherosclerosis: The Role of Inflammation
Current Pharmaceutical Design The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Impact of Fc Receptors on the Development of Autoimmune Diseases
Current Pharmaceutical Design Rheumatologic Manifestations of Hematologic Neoplasms
Current Rheumatology Reviews Mouse Models of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Current Pharmaceutical Design Biomarkers Determining Cardiovascular Risk in Patients with Kidney Disease
Current Medicinal Chemistry Insulin-Degrading Enzyme: Structure-Function Relationship and its Possible Roles in Health and Disease
Current Pharmaceutical Design Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Polyphenolic Compounds and Gut Microbiome in Cardiovascular Diseases
Current Pharmaceutical Biotechnology Use of Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging in Drug Development for Ischemic Stroke
Current Drug Targets - CNS & Neurological Disorders Novel Aspects in the Pathophysiology of Peripheral Vasculopathy in Systemic Sclerosis
Current Rheumatology Reviews Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews The Rationale and Development of New Drugs to Treat HIV Infection
Medicinal Chemistry Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine Cardiac and Muscular Involvement in Idiopathic Inflammatory Myopathies: Noninvasive Diagnostic Assessment and the Role of Cardiovascular and Skeletal Magnetic Resonance Imaging
Inflammation & Allergy - Drug Targets (Discontinued) Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Pharmacogenomics: A Tool to Prevent and Cure Coronary Heart Disease
Current Pharmaceutical Design